7 results on '"Kiyoshi Yoshino"'
Search Results
2. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients
- Author
-
Akiko, Otake, Kiyoshi, Yoshino, Yutaka, Ueda, Kenjiro, Sawada, Seiji, Mabuchi, Toshihiro, Kimura, Eiji, Kobayashi, Aki, Isobe, Tomomi, Egawa-Takata, Shinya, Matsuzaki, Masami, Fujita, and Tadashi, Kimura
- Subjects
Adult ,Ovarian Neoplasms ,Analgesics ,Paclitaxel ,Peripheral Nervous System Diseases ,Thiophenes ,Middle Aged ,Duloxetine Hydrochloride ,Antineoplastic Agents, Phytogenic ,Treatment Outcome ,Humans ,Female ,Aged ,Retrospective Studies - Abstract
The present study aimed at evaluating the usefulness and adverse effects of duloxetine treatment for paclitaxel-induced peripheral neuropathy in gynecological cancer patients.Medical records of gynecological cancer patients treated with duloxetine were retrospectively studied to evaluate the drug's efficacy for paclitaxel-induced peripheral neuropathy.RESULTS from 25 patients showed that an improved response was observed in 14 (56%). By univariate and multivariate analysis, the patient's age, tumor origin, regimen of chemotherapy, accumulated doses of paclitaxel or carboplatin, previous medication, maintenance dosage and timing of treatment with duloxetine were found not to be associated with the effectiveness of duloxetine treatment. Adverse effects with duloxetine were mild and well-tolerated.As an option, duloxetine can be effectively used for paclitaxel-induced peripheral neuropathy in patients with gynecological cancers, irrespective of patients' age, origin of the tumor, regimen of chemotherapy, or previous medication.
- Published
- 2015
3. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience
- Author
-
Akiko, Morimoto, Yutaka, Ueda, Takeshi, Yokoi, Yuki, Tokizawa, Kiyoshi, Yoshino, Masami, Fujita, Toshihiro, Kimura, Eiji, Kobayashi, Shinya, Matsuzaki, Tomomi, Egawa-Takata, Kenjiro, Sawada, Tateki, Tsutsui, and Tadashi, Kimura
- Subjects
Adult ,Aged, 80 and over ,Genital Neoplasms, Female ,Heparin ,Cost-Benefit Analysis ,Anticoagulants ,Venous Thromboembolism ,Heparin, Low-Molecular-Weight ,Middle Aged ,Fondaparinux ,Japan ,Polysaccharides ,Humans ,Female ,Perioperative Period ,Aged - Abstract
To analyze clinical characteristics of venous thromboembolisms (VTE) in gynecological malignancies, and to find a cost-effective prophylaxis procedure for post-operative VTE.We analyzed clinical characteristics of 751 patients who underwent definitive surgery for gynecologic malignancies, and cost-effectiveness of VTE prophylaxis.VTE was diagnosed preoperatively in 4.5% of ovarian cancer cases, more frequently than any other type (p0.005). Older age and greater length of operation were independent risk factors for postoperative VTE. To prevent eight VTEs in 738 malignant cases, which occurred during day 2 to 10, $617,783, $726,185, or $994,222 were necessary for continuous VTE prophylaxis, using either unfractionated heparin (UFH), low-molecular weight heparin or fondaparinux, respectively.A strategy which might be cost-effective for post-surgical management of gynecological malignances is use of UFH three times combined with graduated compression stockings and intermittent pneumatic compression, thorough SpO2 monitoring, and perioperative measurements of the circumference of both sides of thighs and calves.
- Published
- 2014
4. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience
- Author
-
Kiyoshi, Yoshino, Kosuke, Hiramatsu, Takayuki, Enomoto, Masami, Fujita, Yutaka, Ueda, Toshihiro, Kimura, Eiji, Kobayashi, Yumiko, Kiyohara, Tateki, Tsutsui, and Tadashi, Kimura
- Subjects
Adult ,Bridged-Ring Compounds ,Ovarian Neoplasms ,Salvage Therapy ,Antimetabolites, Antineoplastic ,Organoplatinum Compounds ,Middle Aged ,Deoxycytidine ,Gemcitabine ,Drug Resistance, Neoplasm ,Humans ,Female ,Taxoids ,Neoplasm Recurrence, Local ,Aged ,Retrospective Studies - Abstract
The purpose of this study was to report on the safety and efficacy of gemcitabine used as salvage chemotherapy for ovarian cancer.From January 2002 to October 2011, 27 patients were treated with gemcitabine for platinum-resistant recurrent ovarian cancer. Gemcitabine (800 mg/m(2)) was given on days 1, 8, and 15 of every 28 days. The patients' medical records were retrospectively reviewed.All 27 patients had previously received paclitaxel/carboplatin doublet and their disease had become platinum-resistant. The median number of previous chemotherapy regimens was 2 (range 1-7). A total of 114 cycles of single-agent gemcitabine were administered, with a median of 3 (range 1-10). No complete responses were observed. Partial response (PR) was observed in five patients (18.5%). Eight patients demonstrated stable disease (SD). The median duration of response for 5 responders was 4 months (range 2-6 months). The median survival time was 15 months. Patients with PR or SD (n=13) had significantly better survival compared with the group with progressive disease (n=14) (p=0.03, by univariate analysis). In addition, multivariate Cox proportional hazards analysis revealed that responses to gemcitabine were a significant factor for survival (hazard ratio=0.08, 95% confidence interval=0.0138 to 0.5614, p=0.01). Cases with hematological toxicity included 10 patients (37.0%) with grade 3/4 neutropenia, 3 patients (11.1%) with grade 3 thrombocytopenia, and 3 patients (11.1%) with grade 3 anemia. Non-hematological toxicity was well-tolerated.Gemcitabine (800 mg/m(2)) used for recurrent ovarian cancer possesses a modest activity and a well-tolerated toxicity.
- Published
- 2012
5. Dissection of unsuspicious para-aortic lymph nodes does not improve prognosis of advanced endometrial carcinoma with intra- or extra-abdominal metastasis
- Author
-
Yutaka, Ueda, Mika, Okazawa, Takayuki, Enomoto, Tomomi, Egawa-Takata, Toshihiro, Kimura, Kiyoshi, Yoshino, Masami, Fujita, Yukinobu, Ohta, Shoji, Kamiura, and Tadashi, Kimura
- Subjects
Adult ,Carcinoma ,Middle Aged ,Prognosis ,Disease-Free Survival ,Endometrial Neoplasms ,Lymphatic Metastasis ,Multivariate Analysis ,Humans ,Female ,Lymph Nodes ,Neoplasm Metastasis ,Aorta ,Aged ,Proportional Hazards Models ,Retrospective Studies - Abstract
The aim of this study was to analyze the significance of dissection of unsuspicious para-aortic lymph nodes (PAN) in patients with advanced endometrial carcinomas with intra- or extra-abdominal metastasis.We conducted a retrospective comparison of the results of PAN dissection versus non-dissection for endometrial carcinomas with macroscopic metastatic lesions beyond the uterus (without significant swelling of the regional lymph nodes, including PAN), whose lesions were completely resected.Disease-free survival and overall survival did not exhibit a significant difference between the two groups. Multivariate Cox proportional hazards analysis demonstrated that PAN dissection was not an independent prognostic factor for survival. The frequency of PAN involvement at the first recurrence did not differ between the two groups.For advanced endometrial carcinomas with macroscopic metastatic lesions beyond the uterus, without significant swelling of regional lymph nodes, PAN dissection may be omitted without a significant adverse effect on prognosis and survival.
- Published
- 2011
6. Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel
- Author
-
Yukari, Miyoshi, Yutaka, Ueda, Akiko, Morimoto, Takuhei, Yokoyama, Shinya, Matsuzaki, Eiji, Kobayashi, Toshihiro, Kimura, Kiyoshi, Yoshino, Masami, Fujita, Takayuki, Enomoto, and Tadashi, Kimura
- Subjects
Adult ,Ovarian Neoplasms ,Salvage Therapy ,Time Factors ,Paclitaxel ,Carcinoma ,Middle Aged ,Irinotecan ,Disease-Free Survival ,Treatment Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Camptothecin ,Female ,Cisplatin ,Aged ,Retrospective Studies - Abstract
The aim of the study was to analyze the effectiveness of salvage chemotherapy for recurring ovarian carcinoma during or after consolidation chemotherapy.During the study period, 12 patients received salvage chemotherapy for recurrence during or after consolidation chemotherapy. These cases were retrospectively reviewed.The response rate for salvage chemotherapy was 67% and was significantly associated with treatment-free interval (TFI) after consolidation (p=0.038). Progression-free survival was also significantly related to TFI (p=0.032). Combination chemotherapy of cisplatin plus irinotecan was effective in all five cases with TFI≥6 months and in three out of seven cases with TFI6 months.Our study provides, for the first time, evidence that effectiveness of salvage chemotherapy for recurrent ovarian carcinoma occurring during or after consolidation chemotherapy can be predicted by TFI, and that combination chemotherapy of cisplatin plus irinotecan is potentially useful for these cases.
- Published
- 2011
7. Disease-free interval after primary treatment predicts prognosis of recurrent endometrial carcinoma
- Author
-
Yutaka, Ueda, Yuki, Matsumura, Tomomi, Egawa-Takata, Takahito, Miyake, Takashi, Miyatake, Kiyoshi, Yoshino, Masami, Fujita, Shinya, Matsuzaki, Takuhei, Yokoyama, Yukari, Miyoshi, Masato, Yamasaki, Takayuki, Enomoto, and Tadashi, Kimura
- Subjects
Adult ,Aged, 80 and over ,Middle Aged ,Disease-Free Survival ,Endometrial Neoplasms ,Survival Rate ,Chemotherapy, Adjuvant ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Radiotherapy, Adjuvant ,Neoplasm Recurrence, Local ,Aged ,Proportional Hazards Models ,Retrospective Studies - Abstract
The aim of this study was to determine if the disease-free interval after initial surgical resection has any useful prognostic value for recurrent endometrial carcinoma patients.Between 1998 and 2007, complete resection of endometrial carcinoma was achieved in 536 cases at the Departments of Obstetrics and Gynecology of the Osaka University and Osaka Rosai Hospitals of Osaka, Japan. Clinical characteristics of these cases were retrospectively reviewed.Recurrence was subsequently detected in 54 cases. Overall survival after recurrence in 27 patients with recurrences earlier than 12 months who received no postoperative therapy, radiation, and chemotherapy as an adjuvant therapy were significantly shorter than that of those with recurrences later than 12 months with similar treatments. Multivariate analysis demonstrated that the disease-free interval was an independent factor for prognosis.We demonstrate a significantly worse prognosis in cases with early versus late recurrence of resected endometrial carcinomas, irrespective of the type of adjuvant therapy.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.